ZAFER PEKKOLAY

Dr. ZAFER PEKKOLAY

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Atherosclerosis
Verified
Journal Article
Closed access
MKMeral Kayikcioglu
Meral Kayikcioglu
LTLale Tokgozoglu
Lale Tokgozoglu
MYMehmet Birhan Yilmaz
Mehmet Birhan Yilmaz
LKLeylagul Kaynar
Leylagul Kaynar
MAMelih Aktan
Melih Aktan
OIOsman Ilhan
Osman Ilhan

11 April 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
ISILGIN YILDIRIM SIMSIR
ILGIN YILDIRIM SIMSIR
BTBeyhan Tüysüz
Beyhan Tüysüz
MOMehmet Nuri Ozbek
Mehmet Nuri Ozbek
STSeher Tanrikulu
Seher Tanrikulu
MGMerve Celik Guler
Merve Celik Guler
BABaris Akinci
Baris Akinci
Aim: To describe the Turkish generalized lipodystrophy (GL) cohort with the frequency of each complication and the death rate during the period of the follow‐up. Methods: This study reports on 72 patients with GL (47 families) registered at different centres in Turkey that cover all regions of the country. The mean ± SD follow‐up was 86 ± 78 months. Results: The Kaplan–Meier estimate of the median time to diagnosis of diabetes and/or prediabetes was 16 years. Hyperglycaemia was not controlled in 37 of 45 patients (82.2%) with diabetes. Hypertriglyceridaemia developed in 65 patients (90.3%). The Kaplan–Meier estimate of the median time to diagnosis of hypertriglyceridaemia was 14 years. Hypertriglyceridaemia was severe (≥ 500 mg/dl) in 38 patients (52.8%). Seven (9.7%) patients suffered from pancreatitis. The Kaplan–Meier estimate of the median time to diagnosis of hepatic steatosis was 15 years. Liver disease progressed to cirrhosis in nine patients (12.5%). Liver disease was more severe in congenital lipodystrophy type 2 (CGL2). Proteinuric chronic kidney disease (CKD) developed in 32 patients (44.4%) and cardiac disease in 23 patients (31.9%). Kaplan–Meier estimates of the median time to diagnosis of CKD and cardiac disease were 25 and 45 years, respectively. Females appeared to have a more severe metabolic disease, with an earlier onset of metabolic abnormalities. Ten patients died during the follow‐up period. Causes of death were end‐stage renal disease, sepsis (because of recurrent intestinal perforations, coronavirus disease, diabetic foot infection and following coronary artery bypass graft surgery), myocardial infarction, heart failure because of dilated cardiomyopathy, stroke, liver complications and angiosarcoma. Conclusions: Standard treatment approaches have only a limited impact and do not prevent the development of severe metabolic abnormalities and early onset of organ complications in GL.

25 April 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ABAdnan Batman
Adnan Batman
DYDilek Yazıcı
Dilek Yazıcı
ODOğuz Dikbaş
Oğuz Dikbaş
KAKemal Ağbaht
Kemal Ağbaht
ESEmre Sedar Saygılı
Emre Sedar Saygılı
MSMustafa - Sahin
Mustafa - Sahin
Context: The aims of the study are to compare characteristics of subacute thyroiditis (SAT) related to different etiologies, and to identify predictors of recurrence of SAT and incident hypothyroidism. Methods: This nationwide, multicenter, retrospective cohort study included 53 endocrinology centers in Turkey. The study participants were divided into either COVID-19–related SAT (Cov-SAT), SARS-CoV-2 vaccine–related SAT (Vac-SAT), or control SAT (Cont-SAT) groups. Results: Of the 811 patients, 258 (31.8%) were included in the Vac-SAT group, 98 (12.1%) in the Cov-SAT group, and 455 (56.1%) in the Cont-SAT group. No difference was found between the groups with regard to laboratory and imaging findings. SAT etiology was not an independent predictor of recurrence or hypothyroidism. In the entire cohort, steroid therapy requirement and younger age were statistically significant predictors for SAT recurrence. C-reactive protein measured during SAT onset, female sex, absence of antithyroid peroxidase (TPO) positivity, and absence of steroid therapy were statistically significant predictors of incident (early) hypothyroidism, irrespective of SAT etiology. On the other hand, probable predictors of established hypothyroidism differed from that of incident hypothyroidism. Conclusion: Since there is no difference in terms of follow-up parameters and outcomes, COVID-19– and SARS-CoV-2 vaccine–related SAT can be treated and followed up like classic SATs. Recurrence was determined by younger age and steroid therapy requirement. Steroid therapy independently predicts incident hypothyroidism that may sometimes be transient in overall SAT and is also associated with a lower risk of established hypothyroidism.

10 December 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
ZPZAFER PEKKOLAY
ZAFER PEKKOLAY
FKFaruk Kılınç
Faruk Kılınç
NGNevzat Gozel
Nevzat Gozel
EÖEbru Önalan
Ebru Önalan
ATAlpaslan Kemal Tuzcu
Alpaslan Kemal Tuzcu
Context: Bone mineral density is normal in acromegalic patients and the cause of increased fracture risk that characterizes active acromegaly is unknown. Objective: This study compared serum sclerostin levels between patients with active acromegaly and healthy individuals. Design, Setting, and Participants: The serum sclerostin levels of patients with active acromegaly were compared with those of healthy volunteers in a cross-sectional study. The mean age of the 30 acromegaly patients (male/female: 14/16) was 47.26 ± 12.52 years (range, 18–64 years) and that of the healthy volunteers (male/female: 17/13) was 44.56 ± 10.74 years (range, 19–62 years). IGF-1 and GH levels were measured using an electrochemiluminescence method, and serum sclerostin levels using an ELISA. The Mann-Whitney U test was used to compare sclerostin levels between the 2 groups. The correlations of sclerostin level with IGF-1 and GH were determined using Spearman’s test. Results: The 2 groups did not differ in age or sex (P > 0.05). The median GH and IGF-1 levels in the patient group were 2.49 ng/mL (range, 0.22–70.00 ng/mL) (interquartile range [IQR], 1.3–4.52) and 338.5 ng/mL (range, 147–911 ng/mL) (IQR, 250–426), respectively. The median GH and IGF-1 levels in the control group were 0.95 ng/mL (range, 0.3-2.3) and 144 ng/mL (range, 98–198), respectively. The median sclerostin level was 29.95 ng/mL (range, 7.5–78.1 ng/mL) (IQR, 14.37–37.47) in the acromegaly group and 22.44 ng/mL (range, 8.45–36.44 ng/mL) (IQR, 13.71–27.52) in the control group (P < 0.05). There was a moderate positive correlation between the sclerostin and IGF-1 levels (rho = 0.54; P < 0.01), and between the sclerostin and GH levels (rho = 0.41; P < 0.05). Conclusions: High sclerostin levels may contribute to the increased fracture risk seen in patients with acromegaly.

24 February 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
ÖBÖzge Besci
Özge Besci
SFSevde Nur Fırat
Sevde Nur Fırat
SÖSamim Özen
Samim Özen
SÇSemra Çağlar Çetinkaya
Semra Çağlar Çetinkaya
LALeyla Akın
Leyla Akın
EOElif Arioglu Oral
Elif Arioglu Oral
Context Homozygous leptin (LEP) and leptin receptor (LEPR) variants lead to childhood-onset obesity. Objective To present new cases with LEP and LEPR deficiency, report the long-term follow-up of previously described patients, and to define, based on all reported cases in literature, genotype-phenotype relationships. Methods Our cohort included 18 patients (LEP = 11, LEPR = 7), eight of whom had been previously reported. A systematic literature review was conducted in July 2022. 42/47 studies on LEP/LEPR were selected. Results Of 10 new cases, two novel pathogenic variants were identified in LEP (c.16delC) and LEPR (c.40+5G>C). Eleven patients with LEP deficiency received metreleptin, four of whom had been treated for over 20 years. One patient developed loss of efficacy associated with neutralizing antibody development. Of 152 patients, including 134 cases from the literature review in addition to our cases, frameshift variants were the most common (48%) in LEP and missense variants (35%) in LEPR. Patients with LEP deficiency were diagnosed at a younger age (3 (9) vs. 7 (13) years, p = 0.02), and had a higher median BMI SD score (3.1 (2) vs. 2.8 (1) kg/m2, p = 0.02), which was more closely associated with frameshift variants (p = 0.02). Patients with LEP deficiency were more likely to have hyperinsulinemia (p = 0.02). Conclusion Frameshift variants were more common in patients with LEP deficiency whereas missense variants were more common in LEPR deficiency. Patients with LEP deficiency were identified at younger ages, had higher BMI SD scores, and had higher rates of hyperinsulinemia than patients with LEPR deficiency. Eleven patients benefited from long-term metreleptin, with one losing efficacy due to neutralizing antibodies.

4 August 2016 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
MŞMuhammed Şahin
Muhammed Şahin
ASAlparslan Sahin
Alparslan Sahin
FKFaruk Kilinc
Faruk Kilinc
HYHarun Yüksel
Harun Yüksel
ZÖZeynep Gürsel Özkurt
Zeynep Gürsel Özkurt
IÇİhsan Çaça
İhsan Çaça